Adagene, Inc. (ADAG)

Market Cap	48.85M
Revenue (ttm)	10.18M
Net Income (ttm)	-73.21M
Shares Out	54.53M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,132
Open	1.13
Previous Close	1.13
Day's Range	1.13 - 1.45
52-Week Range	0.9 - 9.7
Beta	n/a
Analysts	Buy
Price Target	16.35 (+1,111.1%)
Earnings Date	n/a

About ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTL...

• Industry: Biotechnology
• IPO Date: Feb 9, 2021
• Employees: 259
• Stock Exchange: NASDAQ
• Ticker Symbol: ADAG

Financial Performance

In 2021, Adagene's revenue was $10.18 million, an increase of 1,351.71% compared to the previous year's $700,913. Losses were -$73.18 million, 72.6% more than in 2020.

Analyst Forecast

According to 10 analysts, the average rating for ADAG stock is "Buy." The 12-month stock price forecast is 16.35, which is an increase of 1,111.11% from the latest price.

Price Target

$16.35

(1,111.11% upside)

Analyst Consensus: Buy